For Brazilian Companies
Translate Brazilian science into investor-ready evidence for Canada and the United States.
Brazil leads the world in commercial agricultural biologicals. The science is strong. What most companies need is a credible bridge into North American capital, regulators, and partners, on terms that respect the work already done.
The Brazil–North America Gateway is that bridge.
Why This Matters
Strong science isn't enough. The framing has to match the market.
Brazil leads. North America hasn't caught up.
Brazil produces more registered biological products than any other market. Most Canadian and U.S. investors only encounter the strongest Brazilian companies after valuations have already climbed, or never at all. That gap is a commercial opportunity for companies that present early and present right.
The science is rarely the problem.
Brazilian R&D culture, field trial depth, and regulatory experience are world-class. What slows companies down is translating that work into the formats Canadian and U.S. investors, strategics, and regulators expect: claim language, IP framing, regulatory pathway, and trial protocols.
Trust closes deals.
North American partners need independent validation before they move. A scientifically credible bridge accelerates conversations that would otherwise stall in due diligence.
How We Help
Three layers, designed to be used in sequence.
01
Readiness Review
Structured assessment across science, regulatory, IP, and go-to-market. Outputs a written readiness brief, a tier recommendation, and the specific gaps to close before approaching North American capital or partners.
02
Technical Translation
We translate Brazilian science into North American-ready evidence. Claim audit, regulatory pathway framing (PMRA, EPA, CFIA), IP landscape across CIPO, USPTO, EPO, INPI, WIPO, and competitive benchmarking.
03
Partner Introductions
Targeted introductions to investors, strategics, and distributors in Canada and the United States, prepared with a QBIView-backed evidence package so the first conversation isn't spent justifying the science.
What You Get
A working evidence package, not a slide deck.
- →QBIView Readiness Brief tailored to your stage and ask
- →Claim and regulatory translation for Canadian and U.S. requirements
- →Independent IP landscape across five jurisdictions
- →Target-partner shortlist with warm introductions
- →Ongoing relationship management across both markets
Pricing is tailored to the scope and complexity of each engagement and discussed during an initial consultation.
Confidential by default. Not sold. Not published. Not shared without permission.
Start the Conversation
Ready to cross the bridge?
Tell us about your company and your North American ambition. We respond within two business days.
Or send a message
We respond within two business days.